Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard-dose versus TDM-guided alectinib dosing in ALK-positive advanced NSCLC
NL-OMON52135Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Primary endpoint: Progression-free survival in low-exposure subgroup. Started Mar 2022; status: recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52135.